RESUMEN
Chronic kidney disease (CKD), secondary to renal fibrogenesis, is a public health burden. The activation of interstitial myofibroblasts and excessive production of extracellular matrix (ECM) proteins are major events leading to end-stage kidney disease. Recently, interleukin-15 (IL-15) has been implicated in fibrosis protection in several organs, with little evidence in the kidney. Since endogenous IL-15 expression decreased in nephrectomized human allografts evolving toward fibrosis and kidneys in the unilateral ureteral obstruction (UUO) model, we explored IL-15's renoprotective role by pharmologically delivering IL-15 coupled or not with its soluble receptor IL-15Rα. Despite the lack of effects on myofibroblast accumulation, both IL-15 treatments prevented tubulointerstitial fibrosis (TIF) in UUO as characterized by reduced collagen and fibronectin deposition. Moreover, IL-15 treatments inhibited collagen and fibronectin secretion by transforming growth factor-ß (TGF-ß)-treated primary myofibroblast cultures, demonstrating that the antifibrotic effect of IL-15 in UUO acts, in part, through a direct inhibition of ECM synthesis by myofibroblasts. In addition, IL-15 treatments resulted in decreased expression of monocyte chemoattractant protein 1 (MCP-1) and subsequent macrophage infiltration in UUO. Taken together, our study highlights a major role of IL-15 on myofibroblasts and macrophages, two main effector cells in renal fibrosis, demonstrating that IL-15 may represent a new therapeutic option for CKD.
Asunto(s)
Subunidad alfa del Receptor de Interleucina-15/uso terapéutico , Interleucina-15/uso terapéutico , Riñón/metabolismo , Nefroesclerosis/prevención & control , Insuficiencia Renal Crónica/tratamiento farmacológico , Animales , Quimiocina CCL2/metabolismo , Colágeno/biosíntesis , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Humanos , Interleucina-15/metabolismo , Interleucina-15/farmacología , Subunidad alfa del Receptor de Interleucina-15/metabolismo , Riñón/patología , Ratones Endogámicos C57BL , Miofibroblastos/efectos de los fármacos , Miofibroblastos/metabolismo , Insuficiencia Renal Crónica/metabolismo , Obstrucción UreteralRESUMEN
Acute kidney injury (AKI)-related fibrosis is emerging as a major driver of chronic kidney disease (CKD) development. Aberrant kidney recovery after AKI is multifactorial and still poorly understood. The accumulation of indoxyl sulfate (IS), a protein-bound uremic toxin, has been identified as a detrimental factor of renal fibrosis. However, the mechanisms underlying IS-related aberrant kidney recovery after AKI is still unknown. The present study aims to elucidate the effects of IS on tubular damage and its involvement in the pathogenesis of AKI-to-CKD transition. Our results showed that serum IS started to accumulate associated with the downregulation of tubular organic anion transporter but not observed in the small-molecule uremic toxins of the unilateral ischemia-reperfusion injury (UIRI) without a contralateral nephrectomy model. Serum IS is positively correlated with renal fibrosis and binding immunoglobulin protein (BiP) and CAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP) expression induction in the UIRI with a contralateral nephrectomy model (UIRI+Nx). To evaluate the effects of IS in the AKI-to-CKD transition, we administered indole, a precursor of IS, at the early stage of UIRI. Our results demonstrated IS potentiates renal fibrosis, senescence-associated secretory phenotype (SASP), and activation of endoplasmic reticulum (ER) stress, which is attenuated by synergistic AST-120 administration. Furthermore, we clearly demonstrated that IS exposure potentiated hypoxia-reperfusion (H/R) induced G2/M cell cycle arrest, epithelial-mesenchymal transition (EMT) and aggravated ER stress induction in vitro. Finally, the ER chemical chaperon, 4-phenylbutyric acid (4-PBA), successfully reversed the above-mentioned AKI-to-CKD transition. Taken together, early IS elimination in the early stage of AKI is likely to be a useful strategy in the prevention and/or treatment of the AKI-to-CKD transition.
Asunto(s)
Lesión Renal Aguda/sangre , Carbono/uso terapéutico , Indicán/antagonistas & inhibidores , Nefroesclerosis/prevención & control , Óxidos/uso terapéutico , Insuficiencia Renal Crónica/prevención & control , Lesión Renal Aguda/complicaciones , Animales , Butilaminas , Carbono/farmacología , Evaluación Preclínica de Medicamentos , Indicán/sangre , Indicán/aislamiento & purificación , Ratones Endogámicos C57BL , Nefroesclerosis/sangre , Nefroesclerosis/etiología , Óxidos/farmacología , Insuficiencia Renal Crónica/etiología , Daño por Reperfusión/sangre , Daño por Reperfusión/etiología , Fenotipo Secretor Asociado a la Senescencia/efectos de los fármacos , Respuesta de Proteína Desplegada/efectos de los fármacosRESUMEN
Sepsis-related acute kidney injury (AKI) is known to be caused by inflammation. We explored the renal protective effects of aerosol inhalation of a hydrogen-rich solution (HRS; hydrogen gas dissolved to saturation in saline) in a mouse model of septic AKI. Septic AKI was induced through 18 hours of cecal ligation and puncture. AKI occurred during the early stage of sepsis, as evidenced by increased blood urea nitrogen and serum creatinine levels, pathological changes, renal fibrosis and renal tubular epithelial cell apoptosis, accompanied by macrophage infiltration and M1 macrophage-associated pro-inflammatory cytokine (Il-6 and Tnf-α) generation in renal tissues. Aerosol inhalation of the HRS increased anti-inflammatory cytokine (Il-4 and Il-13) mRNA levels in renal tissues and promoted macrophage polarization to the M2 type, which generated additional anti-inflammatory cytokines (Il-10 and Tgf-ß). Ultimately, aerosol inhalation of HRS protected the kidneys and increased survival among septic mice. HRS was confirmed to promote M2 macrophage polarization in lipopolysaccharide-stimulated RAW 264.7 cells. The TGF-ß1 receptor inhibitor SB-431542 partly reversed the effects of HRS on renal function, fibrosis, tubular epithelial cell apoptosis and senescence in mice. Thus, HRS aerosol inhalation appears highly useful for renal protection and inflammation reduction in septic AKI.
Asunto(s)
Lesión Renal Aguda/terapia , Hidrógeno/administración & dosificación , Macrófagos/efectos de los fármacos , Sepsis/complicaciones , Lesión Renal Aguda/sangre , Lesión Renal Aguda/inmunología , Lesión Renal Aguda/mortalidad , Administración por Inhalación , Animales , Citocinas/efectos de los fármacos , Citocinas/metabolismo , Evaluación Preclínica de Medicamentos , Riñón/efectos de los fármacos , Riñón/metabolismo , Ratones , Ratones Endogámicos C57BL , Nefroesclerosis/etiología , Nefroesclerosis/prevención & control , Oxígeno/sangre , Células RAW 264.7RESUMEN
Virtually all chronic kidney diseases progress towards tubulointerstitial fibrosis. In vitro, Y-box protein-1 (YB-1) acts as a central regulator of gene transcription and translation of several fibrosis-related genes. However, it remains to be determined whether its pro- or antifibrotic propensities prevail in disease. Therefore, we investigated the outcome of mice with half-maximal YB-1 expression in a model of renal fibrosis induced by unilateral ureteral obstruction. Yb1+/- animals displayed markedly reduced tubular injury, immune cell infiltration and renal fibrosis following ureteral obstruction. The increase in renal YB-1 was limited to a YB-1 variant nonphosphorylated at serine 102 but phosphorylated at tyrosine 99. During ureteral obstruction, YB-1 localized to the cytoplasm, directly stabilizing Col1a1 mRNA, thus promoting fibrosis. Conversely, the therapeutic forced nuclear compartmentalization of phosphorylated YB-1 by the small molecule HSc025 mediated repression of the Col1a1 promoter and attenuated fibrosis following ureteral obstruction. Blunting of these effects in Yb1+/- mice confirmed involvement of YB-1. HSc025 even reduced tubulointerstitial damage when applied at later time points during maximum renal damage. Thus, phosphorylation and subcellular localization of YB-1 determines its effect on renal fibrosis in vivo. Hence, induced nuclear YB-1 shuttling may be a novel antifibrotic treatment strategy in renal diseases with the potential of damage reversal.
Asunto(s)
Alcadienos/uso terapéutico , Nefroesclerosis/metabolismo , Factores de Transcripción/metabolismo , Animales , Evaluación Preclínica de Medicamentos , Masculino , Ratones Endogámicos C57BL , Ratones Noqueados , Nefroesclerosis/etiología , Nefroesclerosis/prevención & control , Obstrucción Ureteral/complicacionesAsunto(s)
Proteína Morfogenética Ósea 7/uso terapéutico , Metilación de ADN/efectos de los fármacos , Proteínas de Unión al ADN/fisiología , Proteínas Activadoras de GTPasa/genética , Silenciador del Gen , Nefroesclerosis/etiología , Nefroesclerosis/prevención & control , Proteínas Proto-Oncogénicas/fisiología , AnimalesRESUMEN
Treating chronic kidney disease (CKD) has been challenging because of its pathogenic complexity. Epoxyeicosatrienoic acids (EETs) are cytochrome P-450-dependent derivatives of arachidonic acid with antihypertensive, anti-inflammatory, and profibrinolytic functions. We recently reported that genetic ablation of soluble epoxide hydrolase (sEH), an enzyme that converts EETs to less active dihydroxyeicosatrienoic acids, prevents renal tubulointerstitial fibrosis and inflammation in experimental mouse models of CKD. Here, we tested the hypothesis that pharmacological inhibition of sEH after unilateral ureteral obstruction (UUO) would attenuate tubulointerstitial fibrosis and inflammation in mouse kidneys and may provide a novel approach to manage the progression of CKD. Inhibition of sEH enhanced levels of EET regioisomers and abolished tubulointerstitial fibrosis, as demonstrated by reduced collagen deposition and myofibroblast formation after UUO. The inflammatory response was also attenuated, as demonstrated by decreased influx of neutrophils and macrophages and decreased expression of inflammatory cytokines keratinocyte chemoattractant, macrophage inflammatory protein-2, monocyte chemotactic protein-1, TNF-α, and ICAM-1 in kidneys after UUO. UUO upregulated transforming growth factor-ß1/Smad3 signaling and induced NF-κB activation, oxidative stress, tubular injury, and apoptosis; in contrast, it downregulated antifibrotic factors, including peroxisome proliferator-activated receptor (PPAR) isoforms, especially PPAR-γ. sEH inhibition mitigated the aforementioned malevolent effects in UUO kidneys. These data demonstrate that pharmacological inhibition of sEH promotes anti-inflammatory and fibroprotective effects in UUO kidneys by preventing tubular injury, downregulation of NF-κB, transforming growth factor-ß1/Smad3, and inflammatory signaling pathways, and activation of PPAR isoforms. Our data suggest the potential use of sEH inhibitors in treating fibrogenesis in the UUO model of CKD.
Asunto(s)
Ácidos Araquidónicos/metabolismo , Benzoatos/uso terapéutico , Epóxido Hidrolasas/antagonistas & inhibidores , Nefroesclerosis/prevención & control , Compuestos de Fenilurea/uso terapéutico , Insuficiencia Renal Crónica/prevención & control , Animales , Benzoatos/farmacología , Presión Sanguínea/efectos de los fármacos , Muerte Celular/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Masculino , Ratones Endogámicos C57BL , Nefroesclerosis/etiología , Nefroesclerosis/metabolismo , Estrés Oxidativo/efectos de los fármacos , Receptores Activados del Proliferador del Peroxisoma/metabolismo , Compuestos de Fenilurea/farmacología , Circulación Renal/efectos de los fármacos , Insuficiencia Renal Crónica/etiología , Insuficiencia Renal Crónica/metabolismo , Obstrucción Ureteral/complicacionesRESUMEN
TGF-ß1, via Smad-dependent or Smad-independent signaling, has a central role in the pathogenesis of renal fibrosis. This pathway has been recognized as a potential target for antifibrotic therapy. Here, we identified GQ5, a small molecular phenolic compound isolated from the dried resin of Toxicodendron vernicifluum, as a potent and selective inhibitor of TGF-ß1-induced Smad3 phosphorylation. In TGF-ß1-stimulated renal tubular epithelial cells and interstitial fibroblast cells, GQ5 inhibited the interaction of Smad3 with TGF-ß type I receptor (TßRI) by blocking binding of Smad3 to SARA, suppressed subsequent phosphorylation of Smad3, reduced nuclear translocation of Smad2, Smad3, and Smad4, and downregulated the transcription of major fibrotic genes such as α-smooth muscle actin (α-SMA), collagen I, and fibronectin. Notably, intraperitoneal administration of GQ5 in rats immediately after unilateral ureteral obstruction (UUO) selectively inhibited Smad3 phosphorylation in UUO kidneys, suppressed renal expression of α-SMA, collagen I, and fibronectin, and resulted in impressive renal protection after obstructive injury. Late administration of GQ5 also effectively attenuated fibrotic lesions in obstructive nephropathy. In conclusion, our results suggest that GQ5 hinders renal fibrosis in rats by selective inhibition of TGF-ß1-induced Smad3 phosphorylation.
Asunto(s)
Catecoles/uso terapéutico , Medicamentos Herbarios Chinos/uso terapéutico , Nefroesclerosis/prevención & control , Proteína smad3/metabolismo , Toxicodendron/química , Factor de Crecimiento Transformador beta1/metabolismo , Proteínas Adaptadoras Transductoras de Señales/metabolismo , Animales , Catecoles/aislamiento & purificación , Catecoles/farmacología , Línea Celular , Evaluación Preclínica de Medicamentos , Medicamentos Herbarios Chinos/aislamiento & purificación , Medicamentos Herbarios Chinos/farmacología , Masculino , Ratones Endogámicos C57BL , Nefroesclerosis/metabolismo , Fosforilación/efectos de los fármacos , Fitoterapia , Distribución Aleatoria , Ratas Sprague-Dawley , Insuficiencia Renal Crónica/tratamiento farmacológico , Obstrucción UreteralRESUMEN
Most patients with essential hypertension do not exhibit substantial renal damage. Renal autoregulation by preventing glomerular transmission of systemic pressures has been postulated to mediate this resistance. Conversely, malignant nephrosclerosis (MN) has been postulated to develop when severe hypertension exceeds a critical ceiling. If the concept is valid, even modest blood pressure (BP) reductions to below this threshold regardless of antihypertensive class (1) should prevent MN and (2) lead to the healing of the already developed MN lesions. Both predicates were tested using BP radiotelemetry in the stroke-prone spontaneously hypertensive rats receiving 1% NaCl as drinking fluid for 4 weeks. Severe hypertension (final 2 weeks average systolic BP, >200 mm Hg) and MN (histological damage score 36±5; n=27) developed in the untreated stroke-prone spontaneously hypertensive rats but were prevented by all antihypertensive classes (enalapril [n=15], amlodipine [n=13], or a hydralazine/hydrochlorothiazide combination [n=15]) if the final 2-week systolic BP remained <190 mm Hg. More impressively, modest systolic BP reductions to 160 to 180 mm Hg (hydralazine/hydrochlorothiazide regimen) initiated at ≈4 weeks in additional untreated rats after MN had already developed (injury score 35±4 in the right kidney removed before therapy) led to a striking resolution of the vascular and glomerular MN injury over 2 to 3 weeks (post-therapy left kidney injury score 9±2, P<0.0001; n=27). Proteinuria also declined rapidly from 122±9.5 mg/24 hours before therapy to 20.5±3.6 mg 1 week later. These data clearly demonstrate the barotrauma-mediated pathogenesis of MN and the striking capacity for spontaneous and rapid repair of hypertensive kidney damage if new injury is prevented.
Asunto(s)
Presión Sanguínea/fisiología , Modelos Animales de Enfermedad , Hipertensión/fisiopatología , Nefroesclerosis/fisiopatología , Amlodipino/farmacología , Animales , Antihipertensivos/farmacología , Presión Sanguínea/efectos de los fármacos , Quimioterapia Combinada , Enalapril/farmacología , Humanos , Hidralazina/farmacología , Hidroclorotiazida/farmacología , Hipertensión/prevención & control , Masculino , Nefroesclerosis/prevención & control , Ratas , Ratas Endogámicas SHR , Valores de Referencia , Resultado del TratamientoRESUMEN
Increased renal expression of periostin, a protein normally involved in embryonic and dental development, correlates with the decline of renal function in experimental models and patient biopsies. Because periostin has been reported to induce cell differentiation, we investigated whether it is also involved in the development of renal disease and whether blocking its abnormal expression improves renal function and/or structure. After unilateral ureteral obstruction in wild-type mice, we observed a progressive increase in the expression and synthesis of periostin in the obstructed kidney that associated with the progression of renal lesions. In contrast, mice lacking the periostin gene showed less injury-induced interstitial fibrosis and inflammation and were protected against structural alterations. This protection was associated with a preservation of the renal epithelial phenotype. In vitro, administration of TGF-ß to renal epithelial cells increased the expression of periostin several-fold, leading to subsequent loss of the epithelial phenotype. Furthermore, treatment of these cells with periostin increased the expression of collagen I and stimulated the phosphorylation of FAK, p38, and ERK 42/44. In vivo delivery of antisense oligonucleotides to inhibit periostin expression protected animals from L-NAME-induced renal injury. These data strongly suggest that periostin mediates renal disease in response to TGF-ß and that blocking periostin may be a promising therapeutic strategy against the development of CKD.
Asunto(s)
Moléculas de Adhesión Celular/fisiología , Nefritis/etiología , Nefroesclerosis/etiología , Animales , Técnicas de Cultivo de Célula , Modelos Animales de Enfermedad , Femenino , Silenciador del Gen , Masculino , Ratones Endogámicos C57BL , Nefritis/metabolismo , Nefritis/prevención & control , Nefroesclerosis/metabolismo , Nefroesclerosis/prevención & control , Podocitos/fisiología , Ratas Sprague-Dawley , Factor de Crecimiento Transformador beta/fisiología , Obstrucción Ureteral/complicaciones , Obstrucción Ureteral/metabolismo , Obstrucción Ureteral/patologíaRESUMEN
Methylation of CpG island promoters is an epigenetic event that can effectively silence transcription over multiple cell generations. Hypermethylation of the Rasal1 promoter contributes to activation of fibroblasts and progression of kidney fibrosis. Here, we explored whether such causative hypermethylation could be reversed through endogenous mechanisms and whether such reversal of hypermethylation is a constituent of the antifibrotic activity of bone morphogenic protein 7 (BMP7). We show that successful inhibition of experimental kidney fibrosis through administration of BMP7 associates with normalization of Rasal1 promoter hypermethylation. Furthermore, this reversal of pathologic hypermethylation was achieved specifically through Tet3-mediated hydroxymethylation. Collectively, our findings reveal a new mechanism that may be exploited to facilitate therapeutic DNA demethylation to reverse kidney fibrosis.
Asunto(s)
Proteína Morfogenética Ósea 7/uso terapéutico , Metilación de ADN/efectos de los fármacos , Proteínas de Unión al ADN/fisiología , Proteínas Activadoras de GTPasa/genética , Silenciador del Gen , Nefroesclerosis/etiología , Nefroesclerosis/prevención & control , Proteínas Proto-Oncogénicas/fisiología , Animales , Biomarcadores/metabolismo , Proteína Morfogenética Ósea 7/metabolismo , Proteína Morfogenética Ósea 7/farmacología , Células Cultivadas , Metilación de ADN/genética , Proteínas de Unión al ADN/genética , Dioxigenasas , Epigénesis Genética , Ratones , Nefroesclerosis/genética , Regiones Promotoras Genéticas , Proteínas Proto-Oncogénicas/genética , Obstrucción Ureteral/etiología , Obstrucción Ureteral/genética , Obstrucción Ureteral/prevención & controlAsunto(s)
Proteína Morfogenética Ósea 7/uso terapéutico , Metilación de ADN/efectos de los fármacos , Proteínas de Unión al ADN/fisiología , Proteínas Activadoras de GTPasa/genética , Silenciador del Gen , Nefroesclerosis/etiología , Nefroesclerosis/prevención & control , Proteínas Proto-Oncogénicas/fisiología , Animales , DioxigenasasAsunto(s)
Proteína Morfogenética Ósea 7/uso terapéutico , Metilación de ADN/efectos de los fármacos , Proteínas de Unión al ADN/fisiología , Proteínas Activadoras de GTPasa/genética , Silenciador del Gen , Nefroesclerosis/etiología , Nefroesclerosis/prevención & control , Proteínas Proto-Oncogénicas/fisiología , AnimalesRESUMEN
OBJECTIVE: To study the effect of Jianpi Qinghua Recipe ( JPQHR) on angiotensin II/NADPH oxidase pathway in 5/6 nephrectomized rat renal failure model and the underlying mechanisms. METHODS: The animals were divided into 4 groups: the sham-operated group, the renal failure group, the JPQHR-treated group and the losartan-treated group. After 60-days therapy, serum nitrogen and creatinine were measured. The expression of angiotensin II type 1 receptor (AT1) protein and the expression of p47phox mRNA in renal tissue was determined. SOD and MDA were also examined. RESULTS: Compared with the sham-operated group, the levels of SCr and serum BUN and the AT1 protein and p47phox mRNA expression in the renal failure group were significantly increased. The activities of SOD in renal tissue from the renal failure group was significantly down-regulated while MDA was up-regulated (P<0.05). Compared with the renal failure group, the levels of SCr and serum BUN and the AT1 protein and p47phox mRNA expression in both JPQHR-treated group and losartan-treated group were significantly decreased. The activities of SOD in renal tissue from JPQHR-treated group and losartan-treated group were significantly up-regulated whereas the content of MDA were down-regulated (P<0.05). Compared with the losartan-treated group, the activities of SOD in renal tissue from the JPQHR-treated group was obviously increased (P<0.05), the decrease in AT1 protein and p47phox mRNA was more evident but not statistically different (P>0.05). The level of SCr and serum BUN and the content of MDA were also not statistically different (P>0.05). CONCLUSION: Through decrease the expression of angiotensin II and NADPH oxidase, JPQHR can reduce the oxidative stress in chronic renal failure and delay the renal fibrosis progression.
Asunto(s)
Angiotensina II/metabolismo , Medicamentos Herbarios Chinos/uso terapéutico , Fallo Renal Crónico/tratamiento farmacológico , NADPH Oxidasas/metabolismo , Nefroesclerosis/prevención & control , Animales , Fallo Renal Crónico/fisiopatología , Masculino , Nefrectomía , Nefroesclerosis/etiología , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/fisiología , Fitoterapia , Ratas , Ratas Sprague-DawleyRESUMEN
BACKGROUND AND AIM: Diabetic nephropathy is the main cause of end-stage renal disease. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), a physiological tetrapeptide hydrolyzed by the angiotensin-converting enzyme (ACE), has antifibrotic effects in the cardiovascular system and in the kidney in experimental models of hypertension, heart failure and renal disease. The aim of the study was to evaluate the effect of Ac-SDKP in diabetic nephropathy and the potential additive effect of Ac-SDKP, when compared to ACE inhibitors alone, on the development of renal fibrosis. METHOD: Diabetes was induced in 28 Sprague-Dawley rats by a single intraperitoneal injection of streptozotocin. Control rats (n = 10) received only buffer solution. An ACE inhibitor (ramipril, 3 mg/kg/day) was administered to 11 diabetic rats. After 2 months, Ac-SDKP (1 mg/kg/day) was administered by osmotic minipumps for 8 weeks to 7 diabetic rats and to 6 diabetic rats treated with ramipril. Osmotic minipumps delivered saline solution in the corresponding sham-treated rats (diabetic rats, n = 10, and ramipril-treated diabetic rats, n = 5). RESULTS: Diabetic rats showed a significant increase in blood glucose level, urinary albumin excretion and renal fibrosis, and a reduction of glomerular nephrin expression with respect to control rats. Ac-SDKP administration significantly reduced renal fibrosis in diabetic rats, without significantly reducing urinary albumin excretion. Ramipril treatment caused a significant decrease in albuminuria and renal fibrosis and restored glomerular nephrin expression. Administration of Ac-SDKP, in addition to ramipril, further reduced renal fibrosis with respect to ramipril alone, while it did not improve the antiproteinuric effect of ramipril. CONCLUSION: Ac-SDKP administration reduces renal fibrosis in diabetic nephropathy. Addition of Ac-SDKP to ACE inhibition therapy improves the reduction of renal fibrosis with respect to ACE inhibition alone, suggesting a beneficial effect of this pharmacological association in diabetic nephropathy.
Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Nefropatías Diabéticas/tratamiento farmacológico , Inhibidores de Crecimiento/uso terapéutico , Nefroesclerosis/prevención & control , Oligopéptidos/uso terapéutico , Albuminuria/tratamiento farmacológico , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Animales , Nefropatías Diabéticas/complicaciones , Evaluación Preclínica de Medicamentos , Tasa de Filtración Glomerular/efectos de los fármacos , Inhibidores de Crecimiento/farmacología , Glomérulos Renales/efectos de los fármacos , Glomérulos Renales/metabolismo , Masculino , Proteínas de la Membrana/metabolismo , Nefroesclerosis/etiología , Oligopéptidos/farmacología , Ramipril/farmacología , Ramipril/uso terapéutico , Ratas , Ratas Sprague-DawleyRESUMEN
PURPOSE: The degree of radiation injury to kidneys which are located within the limits of radiotherapy area is determined by the volume and the dose of radiation to which the organ is exposed. When the tolerance dose of the kidney is exceeded after a latent period of 6 months acute nephritis develops and after 18 months chronic nephritis ensues. Melatonin is known to prevent the oxidative injury of toxins and radiotherapy with its free radical scavenging capacity. METHODS AND MATERIALS: In this study 8 weeks old 24 Sprague -Dawley rats were allocated into 4 groups: Control group; Radiotherapy group (20 Gy bilaterally in 5 fractions); Melatonin group (10 mg/kg intraperitoneally), and Melatonin+radiotherapy group (20 Gy Radiotherapy in 5 fractions+ melatonin 10 mg/kg intraperitoneally). After a follow-up period of 6 months BUN was determined in all groups. After rats were euthanized the kidneys were removed for histopathological examination under both light and electron microscopes. RESULTS: After 6 months follow-up, both at light and electron microscopy levels, the rats in radiotherapy+melatonin group were significantly protected against the radiation injury comparing to radiotherapy group (p<0.05). CONCLUSION: It was shown in this experimental model that melatonin has protective effects against radiation injury to kidneys.
Asunto(s)
Antioxidantes/uso terapéutico , Rayos gamma/efectos adversos , Melatonina/uso terapéutico , Nefroesclerosis/prevención & control , Traumatismos por Radiación/prevención & control , Protectores contra Radiación/uso terapéutico , Insuficiencia Renal/prevención & control , Animales , Masculino , Nefroesclerosis/etiología , Traumatismos por Radiación/etiología , Ratas , Ratas Sprague-Dawley , Insuficiencia Renal/etiologíaRESUMEN
BACKGROUND: Activated protein C (APC) can regulate immune and inflammatory responses and apoptosis. Protein C transgenic mice develop less diabetic nephropathy but whether exogenous administration of APC suppresses established diabetic nephropathy is unknown. OBJECTIVES: We investigated the therapeutic potential of APC in mice with streptozotocin-induced diabetic nephropathy. METHODS: Diabetes was induced in unilaterally nephrectomized C57/Bl6 mice using intraperitoneal (i.p.) injection of streptozotocin. Four weeks later, the mice were treated with i.p. exogenous APC every other day for 1 month. RESULTS: APC-treated mice had a significantly improved blood nitrogen urea-to-creatinine ratio, urine total protein to creatinine ratio and proteinuria, and had significantly less renal fibrosis as measured by the levels of collagen and hydroxyproline. The renal tissue concentration of monocyte chemoattractant protein-1 (MCP-1), vascular endothelial growth factor (VEGF) and the RNA expression of platelet-derived growth factor (PDGF), transforming growth factor-ß1 and connective tissue growth factor (CTGF) were significantly lower in APC-treated mice than in untreated animals. The percentage of apoptotic cells was reduced and the expression of podocin, nephrin and WT-1 in the glomeruli was significantly improved in mice treated with APC compared with untreated mice. The levels of coagulation markers were not affected by APC treatment. CONCLUSION: Exogenous APC improves renal function and mitigates pathological changes in mice with diabetic nephropathy by suppressing the expression of fibrogenic cytokines, growth factors and apoptosis, suggesting its potential usefulness for the therapy of this disease.
Asunto(s)
Diabetes Mellitus Experimental/tratamiento farmacológico , Nefropatías Diabéticas/prevención & control , Riñón/efectos de los fármacos , Proteína C/farmacología , Animales , Apoptosis/efectos de los fármacos , Biomarcadores/sangre , Presión Sanguínea/efectos de los fármacos , Quimiocinas/metabolismo , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/complicaciones , Nefropatías Diabéticas/sangre , Nefropatías Diabéticas/etiología , Nefropatías Diabéticas/patología , Nefropatías Diabéticas/fisiopatología , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Esquema de Medicación , Fibrosis , Humanos , Inyecciones Intraperitoneales , Péptidos y Proteínas de Señalización Intercelular/metabolismo , Riñón/metabolismo , Riñón/patología , Riñón/fisiopatología , Masculino , Ratones , Ratones Endogámicos C57BL , Nefrectomía , Nefroesclerosis/etiología , Nefroesclerosis/prevención & control , Tamaño de los Órganos/efectos de los fármacos , Proteína C/administración & dosificación , Estreptozocina , Factores de TiempoRESUMEN
AIM: To investigate the effects of lentivirus-mediated shRNA targeting collagen type I on the mesangial cells of rats and the feasibility of lentivirus-mediated shRNA delivery through renal parenchyma injection. METHODS: Anti-collagen type I shRNA lentiviral vector was constructed, and rat mesangial cells were transfected with transfection enhancer (control group), blank lentiviral vectors (pSC-GFP group), and pSC-GFP/Col I lentiviral vectors (pSC-GFP/Col I group). Transfection efficiency and cell cycle were determined by flow cytometry. RT-PCR and Western blot were performed to detect the mRNA and protein expressions of Col I. Cell proliferation was evaluated by 3-(4,5)-dimethylthiahiazo-3, 5-di-phenytetrazolium-romide (MTT) assay and direct counting, and apoptosis was detected using AnnexinV/PE staining. The feasibility of renal parenchyma injection of lentiviral vectors was assessed. RESULTS: The transfection efficiency was 75.42%. The expressions of collagen type I in pSC-GFP/Col I group was markedly decreased when compared with the other two groups. PSC-GFP/Col I group was higher than pSC-GFP group in the inhibition efficiency of mesangial cell after transfection. Results revealed that pSC-GFP/Col I transfection induced apoptosis to a certain extent. The proportion of cells in G2/M phase in pSC-GFP/Col I group and pSC-GFP group was higher than that in control group after of transfection. Moreover, cells arrested in S phase were markedly increased. Our results also revealed renal injection of lentivirus-mediated shRNA was feasible. CONCLUSION: Lentivirus-mediated shRNA targeting collagen type I could stably and efficiently transfect rat mesangial cells and significantly suppressed collagen type I expressions with acceptable safety. Renal injection of Col I lentivirus-mediated shRNA was also feasible.
Asunto(s)
Colágeno Tipo I/metabolismo , Células Mesangiales/efectos de los fármacos , Nefroesclerosis/prevención & control , ARN Interferente Pequeño/uso terapéutico , Animales , Apoptosis/efectos de los fármacos , Ciclo Celular/efectos de los fármacos , Vectores Genéticos , Proteínas Fluorescentes Verdes , Lentivirus , Masculino , Células Mesangiales/metabolismo , ARN Mensajero/metabolismo , ARN Interferente Pequeño/farmacología , Ratas , Ratas Sprague-Dawley , Sales de Tetrazolio , Tiazoles , TransfecciónAsunto(s)
Nefroesclerosis/epidemiología , Anciano , Anciano de 80 o más Años , Arteriolas/patología , Nefropatías Diabéticas/complicaciones , Nefropatías Diabéticas/epidemiología , Progresión de la Enfermedad , Femenino , Predisposición Genética a la Enfermedad , Humanos , Hipertensión/complicaciones , Hipertensión/tratamiento farmacológico , Riñón/irrigación sanguínea , Fallo Renal Crónico/etiología , Masculino , Nefroesclerosis/complicaciones , Nefroesclerosis/diagnóstico , Nefroesclerosis/genética , Nefroesclerosis/prevención & control , Grupos Raciales/estadística & datos numéricos , Estudios Retrospectivos , Factores de RiesgoRESUMEN
Transforming growth factor-beta (TGF-beta) has a pivotal function in the progression of renal fibrosis in a wide variety of renal diseases. Smad proteins have been identified to have an important function in regulating the expression of extracellular matrix (ECM) proteins through TGF-beta signaling pathway. Aberrant TGF-beta/Smad signaling can be modulated by stabilization of microtubules with paclitaxel. In this study, we investigated if paclitaxel can attenuate tubulointerstitial fibrosis in a rat model of unilateral ureteral obstruction (UUO). Rats in groups of six were subjected to UUO and received low-dose intraperitoneal injection of paclitaxel (0.3 mg/kg) twice a week. They were killed at day 7 and 14 after UUO or Sham operation. TGF-beta signaling cascade and status of various ECM proteins were evaluated by RT-PCR, western blotting and immunohistochemical or immunofluorescence staining. The paclitaxel treatment markedly suppressed Smad2 and Smad3 phosphorylation. This was associated with attenuated expression of integrin-linked kinase, collagens I and III, fibronectin (FN) and alpha-smooth muscle actin, and a substantial decrease in renal fibrosis in animals that underwent UUO and received paclitaxel. These data indicate that the low-dose paclitaxel ameliorates renal tubulointerstitial fibrosis by modulating TGF-beta signaling, and thus, the paclitaxel may have some therapeutic value in humans.
Asunto(s)
Nefroesclerosis/prevención & control , Paclitaxel/uso terapéutico , Proteínas Smad/antagonistas & inhibidores , Factor de Crecimiento Transformador beta/antagonistas & inhibidores , Moduladores de Tubulina/uso terapéutico , Animales , Matriz Extracelular/metabolismo , Riñón/patología , Masculino , Nefroesclerosis/etiología , Nefroesclerosis/patología , Paclitaxel/farmacología , Ratas , Ratas Wistar , Transducción de Señal/efectos de los fármacos , Moduladores de Tubulina/farmacología , Obstrucción Ureteral/complicacionesRESUMEN
Tubulointerstitial fibrosis (TIF) is a common pathological feature of end-stage kidney disease. Previous studies showed that upregulation of TGFbeta1 notably contributed to the chronic renal injury and irbesartan halted the development of TIF in rats with 5/6 renal mass reduction. This study was to investigate the effects of irbesartan on chronic TIF and the mechanism involved TGFbeta1 in the rodent model of chronic renal failure involving 5/6 nephrectomy. The results showed that irbesartan significantly attenuated the rise in blood pressure and tubulointerstitial injury observed in this model. Masson staining of the renal tissue revealed that there appeared severe renal tubule atrophy and fibrosis in operation group, but the lesion was attenuated mostly in irbesartan-treated group. Immunohistochemistry showed that irbesartan treatment apparently decreased the protein expression of TGFbeta1 which was up-regulated in operation groups. Western blot showed that irbesartan treatment down-regulated the expression of TGFbeta1, phosphorylated smad2 (p-smad2), AT1R and phosphorylated p38 (p-p38) MAPK, but significantly up-regulated the protein expression of smad6 as compared with operation group. These findings suggest that irbesartan attenuates hypertension and reduces the development of TIF in rats with 5/6 renal mass reduction via changes in the expression of these proteins at least including smad6, TGF-beta1, p-smad2, AT1 and p-p38 MAPK.